Clinical Trials Logo

Rabies Human clinical trials

View clinical trials related to Rabies Human.

Filter by:
  • None
  • Page 1

NCT ID: NCT06177249 Completed - Rabies Human Clinical Trials

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

rabies
Start date: March 15, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the safety and immunogenicity of lyophilized human rabies vaccine (Vero cell) developed by Hualan Biological in healthy people aged 9 to 65 years with two different immunization schedules.

NCT ID: NCT05549908 Completed - Rabies Human Clinical Trials

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Start date: July 22, 2020
Phase: Phase 3
Study type: Interventional

A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)

NCT ID: NCT05545371 Enrolling by invitation - Rabies Human Clinical Trials

Prevention of Rabies With Four Doses of Rabies Vaccine

Start date: June 18, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the non inferiority of the immunogenicity of the test vaccine inoculated according to the four dose immunization program over the five dose immunization program and the batches consistency of immunogenicity according to five dose immunization procedures.

NCT ID: NCT05382650 Recruiting - Pediatrics Clinical Trials

Survey of Human Rabies Immune Globulin Safety in Children

Start date: February 22, 2023
Phase:
Study type: Observational

This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.

NCT ID: NCT04495569 Completed - Vaccine Reaction Clinical Trials

A Bridging Study of the SYN023 on Healthy Adult Subjects

Start date: February 26, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023) alone or combined with rabies vaccine in healthy subjects. The study primary purpose was to compare the pharmacokinetics (PK) between U.S and China subjects, therefore to lay a foundation for the follow-up clinical trials. The secondary purpose was to evaluate the PK, PD, Safety and ADA of SYN023 in Chinese Healthy subjects and compare with that of U.S. subjects.

NCT ID: NCT04213950 Completed - Rabies Clinical Trials

Improving Adherence to Rabies PEP Guideline Recommendations

Start date: December 29, 2019
Phase: N/A
Study type: Interventional

This quasi-experimental, quality improvement study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED). Previous research identified opportunities to improve patient selection and delivery of rabies immune globulin (IG) as recommended by Centers for Disease Control and Prevention (CDC) guideline recommendations for rabies postexposure prophylaxis (PEP). The purpose of this study is to develop, implement, and measure the impact of a quality improvement bundle that consists of (1) rabies PEP electronic health records (EHR) enhancements, (2) education to ED staff, and (3) education to patients. Adherence to quality indicators, which are based on CDC guideline recommendations, for patient selection and delivery of rabies IG for 12 months following implementation (post-implementation group) will be compared with a historical control group.

NCT ID: NCT03557008 Completed - Rabies Human Clinical Trials

Responses to Rabies Vaccine in Adults With or Without Antibiotics

Start date: July 5, 2018
Phase: Phase 4
Study type: Interventional

The use of antibiotics changes micro-organisms in the intestines which may impact the body's vaccine immune response and alter the effectiveness of the rabies vaccine. There will be two randomized groups (1:1 randomization). Group A will start taking an antibiotic regimen by mouth 3 days prior to vaccination and continue taking antibiotics the day of rabies vaccination and one day after vaccination for a total of 5 days. Group B will only receive the rabies vaccination and will not take any antibiotics. The dosage of each antibiotic is taken from their respective package inserts and does not exceed the maximum dose allowed for each antibiotic. The purpose of the study is to look at immune response after rabies vaccination with or without the use of antibiotics from day of vaccination to 28 days post vaccination in both groups.